At the Intersection of Technology, Law, and Business
  • - Artificial Intelligence

    AI Leaders Commit to White House Supported Guidelines

    By: Tessa Schwartz

    In coordination with the White House , several leaders in the artificial intelligence (AI) space have publicly committed to a voluntary set of guidelines relating to responsible development and deployment of AI. Amazon, Anthropic, Google, Inflection, Meta, Microsoft, and OpenAI made immediate public commitments
    ... ›
  • Generative AI and Copyright: Roundtable Series Recap
    - Artificial Intelligence

    Generative AI and Copyright: Roundtable Series Recap

    By: Justin H. Haan, Joseph C. Gratz, Anthony M. Ramirez, Aaron P. Rubin, Stephanie Lynn Sharron and Roman A. Swoopes

    Throughout April, Morrison Foerster sponsored and participated in a series of roundtable discussions hosted by Creative Commons regarding generative AI and copyright. The roundtables—in Boston, New York, and San Francisco—brought together in-house counsel from companies developing generative AI tools, scholars, business leaders, and nonprofit advisors.
    ... ›
  • FDA Publishes Draft Guidance for Predetermined Change Control Plan for AI/ML-Enabled Device Software Functions
    - Artificial Intelligence

    FDA Publishes Draft Guidance for Predetermined Change Control Plan for AI/ML-Enabled Device Software Functions

    By: Brigid DeCoursey Bondoc and Brandy A. Guarda

    On April 3, 2023, FDA released the draft guidance titled “ Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions ” (hereinafter “draft guidance”) proposing an approach to support iterative improvement through modifications to a machine
    ... ›
  • 10 Considerations When Licensing AI For Drug Discovery
    - Artificial Intelligence

    10 Considerations When Licensing AI For Drug Discovery

    By: Stephanie Lynn Sharron, Annalisa Elizabeth Cooper, Wolfgang Schönig and Robert Grohmann

    Stephanie Sharron, Annalisa Cooper, and Wolfgang Schoenig, with assistance from Robert Grohmann, authored an article for Law360 explaining the top ten considerations when licensing AI for drug discovery. The ten considerations are: Consider the nature of the services being provided. Be mindful of IP
    ... ›
  • Key Issues in Generative AI Transactions
    - Artificial Intelligence

    Key Issues in Generative AI Transactions

    By: Aaron P. Rubin

    Over the past year, we have seen a dramatic increase in the adoption of AI technologies across industries. Because transactions involving AI technologies can resemble those involving traditional software, like SaaS agreements, parties often assume that their expectations from those standard agreements about what
    ... ›
  • Responsible AI as Part of a Company's ESG Framework
    - Artificial Intelligence

    Responsible AI as Part of a Company's ESG Framework



    By: Susan H. Mac Cormac, Stephanie Lynn Sharron and Oluwabamise A. Onabanjo

    Suz Mac Cormac, Stephanie Sharron, and Oluwabamise Onabanjo authored an article for the Daily Journal explaining how Responsible AI (artificial intelligence) practices in combination with Environmental, Social, and Governance (ESG) frameworks can be applied both to mitigate risk and support a corporation's ESG goals.
    ... ›
  • Generative AI and Copyright: Conference Recap
    - Artificial Intelligence

    Generative AI and Copyright: Conference Recap

    By: Justin H. Haan, Joseph C. Gratz and Allyson R. Bennett

    On March 24, thought leaders in the technology and entertainment industries gathered in Los Angeles and virtually for Creative Commons’ Disruption Conference. The daylong event, which was sponsored by Morrison Foerster, focused on how the rights of content creators are being transformed as generative AI
    ... ›